within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM05_Parsaclisib;
model Parsaclisib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EM05;

  annotation(Documentation(
    info ="<html><body><p>Parsaclisib is an oral, selective PI3Kδ inhibitor developed for the treatment of relapsed or refractory B-cell malignancies, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. It is not broadly FDA approved as of June 2024, but has been studied in clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult patients with B-cell malignancies receiving oral parsaclisib. Most PK data are from phase 1/2 clinical trials in this patient population.</p><h4>References</h4><ol><li><p>Li, J, et al., &amp; Yeleswaram, S (2020). An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants. <i>Journal of clinical pharmacology</i> 60(11) 1519–1526. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1653&quot;>10.1002/jcph.1653</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32515832/&quot;>https://pubmed.ncbi.nlm.nih.gov/32515832</a></p></li><li><p>Fukuhara, N, et al., &amp; Izutsu, K (2022). Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study. <i>Cancer science</i> 113(5) 1702–1711. DOI:<a href=&quot;https://doi.org/10.1111/cas.15308&quot;>10.1111/cas.15308</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35201656/&quot;>https://pubmed.ncbi.nlm.nih.gov/35201656</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Parsaclisib;
